Skip to content
Peptigraph home
Shop Peptides50% off*

Tirzepatide Benefits: Claims vs What Studies Show

Benefits people claim for Tirzepatide, set against what published studies measured, and where no study exists.

Medical review pendingGLP-1 / GIP dual agonistUpdated
Strongest evidence
Human RCT
Human / animal studies
24 / 0
in our evidence file (PubMed search, 2 Oct 2026)
FDA status
Approved (Mounjaro, Zepbound)

Claimed benefits and what studies show

Each row is an area where people claim a benefit, with the strongest study we summarise behind it. Animal and cell results are labelled and are not human results. User reports are not counted as evidence here.

Tirzepatide claimed benefits and the studies behind them
ClaimBest evidenceStudies (human / animal)What was measuredPage
Weight lossHuman RCT evidence, 4 of 413 / 0Joint response plus weight loss; Weight change vs semaglutide; Waist circumferenceEvidence for weight loss
DiabetesHuman RCT evidence, 4 of 47 / 0Cardiovascular death, MI or stroke; Body weight change; HbA1c changeEvidence for diabetes
Heart healthHuman RCT evidence, 4 of 45 / 0Cardiovascular death, MI or stroke; Cardiovascular death or worsening heart failure; Quality of life (KCCQ-CSS)Evidence for heart health
Muscle growthHuman RCT evidence, 4 of 41 / 0Fat mass and lean mass; Share of weight lost as fat; Lean mass loss with GLP-1 agonistsEvidence for muscle growth
BodybuildingHuman RCT evidence, 4 of 41 / 0Fat mass and lean mass; Share of weight lost as fat; Lean mass loss with GLP-1 agonistsEvidence for bodybuilding
Liver healthHuman RCT evidence, 4 of 43 / 0Resolution of MASH without worsening of fibrosis; Liver fat content; Visceral and abdominal fatEvidence for liver health
MetabolismHuman RCT evidence, 4 of 42 / 0Fat mass and lean mass; Triglycerides and metabolites; Lean mass loss with GLP-1 agonistsEvidence for metabolism
Joint painHuman RCT evidence, 4 of 41 / 0Joint response plus weight loss; ACR50 responseEvidence for joint pain
DepressionHuman RCT evidence, 4 of 41 / 0Depressive symptoms (PHQ-9); Suicidal ideationEvidence for depression
TestosteroneHuman RCT evidence, 4 of 41 / 0Gonadal hormones and sexual function; Testosterone and gonadotropinsEvidence for testosterone
Hormone balanceHuman RCT evidence, 4 of 41 / 0Gonadal hormones and sexual function; Testosterone and gonadotropinsEvidence for hormone balance
MenHuman RCT evidence, 4 of 41 / 0Gonadal hormones and sexual function; Testosterone and gonadotropinsEvidence for men
sleep apneaHuman RCT evidence, 4 of 41 / 0Apnea-hypopnea index, trial 1 (no PAP); Apnea-hypopnea index, trial 2 (on PAP)Evidence for sleep apnea
AnxietyHuman RCT evidence, 4 of 41 / 0Depressive symptoms (PHQ-9)Evidence for anxiety
Erectile dysfunctionHuman RCT evidence, 4 of 41 / 0Gonadal hormones and sexual functionEvidence for erectile dysfunction
OsteoporosisHuman observational evidence, 3 of 41 / 0Osteoporosis or fragility fractureEvidence for osteoporosis
InflammationReview only0 / 0hsCRP and IL-6Evidence for inflammation

Strongest study per claim: Weight loss, Arthritis & rheumatology 2026, PMID 41903163; Diabetes, The New England journal of medicine 2025, PMID 41406444; Heart health, The New England journal of medicine 2025, PMID 41406444.

What the studies measured

Tirzepatide outcomes in published studies
OutcomeResultStudy typeSource
Joint response plus weight lossThe combined joint-response and weight-reduction end point was met by 31.7% on ixekizumab plus tirzepatide vs 0.8% on ixekizumab alone.Human RCTn = 271Arthritis & rheumatology 2026, PMID 41903163
ACR50 responseACR50 response was 33.5% with ixekizumab plus tirzepatide vs 20.4% with ixekizumab alone.Human RCTn = 271Arthritis & rheumatology 2026, PMID 41903163
Depressive symptoms (PHQ-9)Fewer tirzepatide participants shifted to a more severe depressive-symptom category (18.2% vs 24.3% with placebo).Human RCTn = 4056Obesity 2026, PMID 41537305
Suicidal ideationSuicidal ideation was reported by 0.6% of participants in each group.Human RCTn = 4056Obesity 2026, PMID 41537305
Weight change vs semaglutideTirzepatide reduced weight by 20.2% versus 13.7% with semaglutide at week 72.Human controlled trialn = 751The New England journal of medicine 2025, PMID 40353578
Waist circumferenceWaist circumference fell by 18.4 cm with tirzepatide versus 13.0 cm with semaglutide.Human controlled trialn = 751The New England journal of medicine 2025, PMID 40353578
Cardiovascular death, MI or strokePrimary events occurred in 12.2% (tirzepatide) vs 13.1% (dulaglutide); hazard ratio 0.92 (95.3% CI 0.83 to 1.01), noninferior but superiority not shown (P = 0.09).Human RCTn = 13165The New England journal of medicine 2025, PMID 41406444
Cardiovascular death or worsening heart failureThe composite occurred in 9.9% on tirzepatide vs 15.3% on placebo (hazard ratio 0.62, 95% CI 0.41 to 0.95).Human RCTn = 731The New England journal of medicine 2025, PMID 39555826
Quality of life (KCCQ-CSS)The symptom score improved by 19.5 with tirzepatide vs 12.7 with placebo, a difference of 6.9 (95% CI 3.3 to 10.6).Human RCTn = 731The New England journal of medicine 2025, PMID 39555826
Fat mass and lean massAt week 72, body weight, fat mass and lean mass changed by -21.3%, -33.9% and -10.9% with tirzepatide vs -5.3%, -8.2% and -2.6% with placebo.Human RCTn = 160Diabetes, obesity & metabolism 2025, PMID 39996356
Share of weight lost as fatAbout 75% of weight lost was fat mass and 25% lean mass, for both tirzepatide and placebo.Human RCTn = 160Diabetes, obesity & metabolism 2025, PMID 39996356
Gonadal hormones and sexual functionAfter 2 months, the tirzepatide group had greater reductions in body weight, waist circumference, binge-eating score and fat mass and a notable increase in lean mass and erectile-function score than the other groups (small pilot).Human controlled trialn = 83Reproductive biology and endocrinology 2025, PMID 40604795
Testosterone and gonadotropinsThe tirzepatide group had higher LH, FSH, SHBG, total, free and bioavailable testosterone and lower estradiol than both comparison groups.Human controlled trialn = 83Reproductive biology and endocrinology 2025, PMID 40604795
Weight maintenance after lead-inFrom week 36 to week 88, weight changed by -5.5% with continued tirzepatide versus 14.0% (regain) after switching to placebo.Human RCTn = 670JAMA 2024, PMID 38078870
Maintained 80% of weight loss89.5% of continuing participants kept at least 80% of lead-in weight loss, versus 16.6% on placebo.Human RCTn = 670JAMA 2024, PMID 38078870
Apnea-hypopnea index, trial 1 (no PAP)Trial 1: AHI fell by 25.3 events per hour with tirzepatide versus 5.3 with placebo at week 52.Human RCTThe New England journal of medicine 2024, PMID 38912654
Apnea-hypopnea index, trial 2 (on PAP)Trial 2: AHI fell by 29.3 events per hour with tirzepatide versus 5.5 with placebo at week 52.Human RCTThe New England journal of medicine 2024, PMID 38912654
Resolution of MASH without worsening of fibrosisMASH resolved without worsening fibrosis in 44% (5 mg), 56% (10 mg) and 62% (15 mg) vs 10% with placebo.Human RCTn = 190The New England journal of medicine 2024, PMID 38856224
Blood pressureBy 72 weeks, blood pressure was 6.8 mm Hg systolic and 4.2 mm Hg diastolic lower than with placebo.Human RCTHeart 2024, PMID 39084707
Role of weight lossWeight loss explained 68% of the systolic and 71% of the diastolic blood pressure reduction.Human RCTHeart 2024, PMID 39084707

Showing the first 20 of 49 rows, strongest sources first.

Not shown in any study we cite. Searches behind this page: PubMed search on 2 Oct 2026 for “tirzepatide[ti] AND (SURMOUNT[tiab] OR SURPASS[tiab]) AND randomized controlled trial[pt]”: 93 results. PubMed search on 2 Oct 2026 for “tirzepatide[ti] AND (SURPASS-2 OR SURPASS-3 OR SURPASS-4 OR SURPASS-5 OR "versus semaglutide" OR "SURPASS-CVOT" OR dulaglutide)”: 143 results. PubMed search on 2 Oct 2026 for “tirzepatide[ti] AND (steatohepatitis OR NASH OR "heart failure" OR HFpEF OR "preserved ejection" OR cardiovascular)”: 410 results. PubMed search on 2 Oct 2026 for “tirzepatide[ti] AND (SURPASS-2 OR SURPASS-3 OR SURPASS-1 OR SURPASS-5 OR "SURPASS J-mono") AND randomized controlled trial[pt]”: 24 results.

The weight-loss claim

Claim: it produces large weight loss. In SURMOUNT-1 the mean weight change at week 72 was -15.0% (5 mg), -19.5% (10 mg) and -20.9% (15 mg), against -3.1% for placebo.[29]

Claim: it beats semaglutide. In SURMOUNT-5, weight changed by -20.2% with tirzepatide against -13.7% with semaglutide, in an open-label trial.[3]

Claim: the weight stays off. SURMOUNT-4 found weight regain after withdrawal while continued treatment maintained and augmented the initial reduction.[8]

The blood sugar claim

Claim: it lowers HbA1c. In SURPASS-1 mean HbA1c decreased by 1.87%, 1.89% and 2.07% at 5, 10 and 15 mg, against +0.04% with placebo.[30]

In SURMOUNT-2, people with obesity and type 2 diabetes lost -12.8% (10 mg) and -14.7% (15 mg) of body weight against -3.2% with placebo.[31]

Sleep apnea, liver and heart claims

Claim: it helps sleep apnea. In the first SURMOUNT-OSA trial the apnea-hypopnea index fell by 25.3 events per hour with tirzepatide against 5.3 with placebo.[9]

The OSA trials' authors also report reductions in hsCRP concentration and systolic blood pressure compared with placebo.[9]

Claim: it helps fatty liver. A post hoc analysis found significant reductions in NASH biomarkers at higher doses in type 2 diabetes.[32]

Claim: it protects the heart. A pooled analysis of the SURPASS programme found a hazard ratio of 0.80 for four-component MACE, with a confidence interval of 0.57-1.11 that does not exclude no difference.[33]

Hormones and muscle claims

Claim: it raises testosterone in men with obesity. A controlled pilot in men with obesity and metabolic hypogonadism reported higher testosterone after 2 months of treatment than the comparison groups.[7]

Claim: it preserves muscle. In a SURMOUNT-1 substudy about 75% of the weight lost was fat mass and 25% lean mass, the same split as placebo.[6]

More on Tirzepatide

DosageSide effectsResultsHow it works

Common questions

Is Tirzepatide proven to work?

The strongest study we summarise for Tirzepatide is human rct evidence, among 30 studies. A trial result is not an approval; see the legal status.

Is tirzepatide proven to work for weight loss?

In the cited randomised trials it beat placebo and semaglutide on weight change; the weight results above are from SURMOUNT-1 and SURMOUNT-5.[3]

More on Tirzepatide

DosageDoses used in published studies, with the source for each.CalculatorVial, water and dose to syringe units.Side effectsWhat labels and studies report, and what is unknown.ResultsStudy outcomes and when they were measured.PricePrice per mg and per week from dated listings. No vendor links.How it worksTarget, mechanism and how long it acts, from the label or studies.

Sources

  1. 1Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical Trial.Arthritis & rheumatology (Hoboken, N.J.) · 2026PMID 41903163Accessed 2 Oct 2026
  2. 2Psychiatric Safety of Tirzepatide in People With Obesity and No Known Major Psychopathology: A Post Hoc Analysis of SURMOUNT.Obesity (Silver Spring, Md.) · 2026PMID 41537305Accessed 2 Oct 2026
  3. 3Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.The New England journal of medicine · 2025PMID 40353578Accessed 2 Oct 2026
  4. 4Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes.The New England journal of medicine · 2025PMID 41406444Accessed 2 Oct 2026
  5. 5Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity.The New England journal of medicine · 2025PMID 39555826Accessed 2 Oct 2026
  6. 6Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight.Diabetes, obesity & metabolism · 2025PMID 39996356Accessed 2 Oct 2026
  7. 7Short-term impact of tirzepatide on metabolic hypogonadism and body composition in patients with obesity: a controlled pilot study.Reproductive biology and endocrinology : RB&E · 2025PMID 40604795Accessed 2 Oct 2026
  8. 8Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial.JAMA · 2024PMID 38078870Accessed 2 Oct 2026
  9. 9Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity.The New England journal of medicine · 2024PMID 38912654Accessed 2 Oct 2026
  10. 10Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis.The New England journal of medicine · 2024PMID 38856224Accessed 2 Oct 2026
  11. 11Tirzepatide and blood pressure reduction: stratified analyses of the SURMOUNT-1 randomised controlled trial.Heart (British Cardiac Society) · 2024PMID 39084707Accessed 2 Oct 2026
  12. 12Association of tirzepatide use with risk of osteoporosis compared with other GLP-1 receptor agonists: A retrospective cohort study using the TriNetX database.Diabetes research and clinical practice · 2025PMID 41218687Accessed 2 Oct 2026
  13. 13Anti-inflammatory effects of tirzepatide: a systematic review and meta-analysis.Reviews in endocrine & metabolic disorders · 2026PMID 41032183Accessed 2 Oct 2026
  14. 14PubMed search: tirzepatide[ti] AND (SURMOUNT[tiab] OR SURPASS[tiab]) AND randomized controlled trial[pt] (93 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  15. 15PubMed search: tirzepatide[ti] AND (SURPASS-2 OR SURPASS-3 OR SURPASS-4 OR SURPASS-5 OR "versus semaglutide" OR "SURPASS-CVOT" OR dulaglutide) (143 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  16. 16PubMed search: tirzepatide[ti] AND (steatohepatitis OR NASH OR "heart failure" OR HFpEF OR "preserved ejection" OR cardiovascular) (410 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  17. 17PubMed search: tirzepatide[ti] AND (SURPASS-2 OR SURPASS-3 OR SURPASS-1 OR SURPASS-5 OR "SURPASS J-mono") AND randomized controlled trial[pt] (24 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  18. 18PubMed search: tirzepatide[ti] AND (steatohepatitis OR "heart failure" OR "SUMMIT" OR "SYNERGY-NASH" OR "phase 2") AND randomized controlled trial[pt] (21 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  19. 19PubMed search: tirzepatide[tiab] AND (meta-analysis[pt] OR systematic review[pt]) AND (weight OR glycemic OR HbA1c OR obesity) (178 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  20. 20PubMed search: tirzepatide[tiab] AND (pharmacokinetic*[tiab] OR half-life[tiab]) AND humans[mh] (49 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  21. 21PubMed search: tirzepatide[ti] AND (insulin degludec OR "SURPASS-3") AND "type 2 diabetes"[ti] AND randomized controlled trial[pt] (8 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  22. 22PubMed search: tirzepatide[ti] AND (cardiovascular outcomes OR "SURPASS-CVOT" OR "major adverse") (228 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  23. 23PubMed search: tirzepatide[tiab] AND (depression OR anxiety OR ADHD OR osteoporosis OR "bone mineral" OR menopause OR "rheumatoid" OR arthritis OR testosterone) (121 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  24. 24PubMed search: tirzepatide[tiab] AND ("body composition"[tiab] OR "lean mass"[tiab] OR "visceral fat"[tiab] OR "fat mass"[tiab]) AND humans[mh] (91 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  25. 25PubMed search: tirzepatide[tiab] AND (blood pressure[tiab] OR cholesterol[tiab] OR lipid*[tiab]) AND (randomized controlled trial[pt] OR meta-analysis[pt]) (58 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  26. 26PubMed search: tirzepatide[tiab] AND (SURPASS-CVOT OR "cardiovascular events" ) AND "dulaglutide"[tiab] AND randomized controlled trial[pt] (6 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  27. 27PubMed search: tirzepatide[tiab] AND (depression[tiab] OR anxiety[tiab] OR "mental health"[tiab] OR ADHD[tiab] OR "binge eating"[tiab]) AND (randomized controlled trial[pt] OR clinical trial[pt]) (3 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  28. 28PubMed search: tirzepatide[tiab] AND (menopaus*[tiab] OR PCOS[tiab] OR "polycystic"[tiab] OR testosterone[tiab] OR hypogonadism[tiab]) (55 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  29. 29Tirzepatide Once Weekly for the Treatment of Obesity.The New England journal of medicine · 2022PMID 35658024Accessed 2 Oct 2026
  30. 30Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.Lancet (London, England) · 2021PMID 34186022Accessed 2 Oct 2026
  31. 31Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.Lancet (London, England) · 2023PMID 37385275Accessed 2 Oct 2026
  32. 32Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes.Diabetes care · 2020PMID 32291277Accessed 2 Oct 2026
  33. 33Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis.Nature medicine · 2022PMID 35210595Accessed 2 Oct 2026

Found an error? Report a correction.